| Code | CSB-RA621524MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to IMT-009, targeting KLRB1 (Killer cell lectin-like receptor subfamily B member 1), also known as CD161. KLRB1 is a C-type lectin receptor expressed on natural killer (NK) cells, NKT cells, and subsets of T lymphocytes, including mucosal-associated invariant T (MAIT) cells and Th17 cells. This receptor functions as an inhibitory or activating molecule depending on cellular context, regulating immune cell activation and cytokine production upon binding to its ligand, lectin-like transcript 1 (LLT1). KLRB1 plays important roles in immune surveillance, inflammatory responses, and has been implicated in autoimmune diseases, cancer immunology, and infectious disease pathogenesis.
The reference antibody IMT-009 has been utilized in immunological research to characterize KLRB1-expressing cell populations and investigate their functional properties in various disease contexts. This biosimilar provides researchers with a reliable tool for studying KLRB1-mediated immune regulation, exploring the role of CD161+ immune cells in disease progression, and investigating potential therapeutic interventions targeting this pathway.
There are currently no reviews for this product.